David E. Neal mainly investigates Prostate cancer, Internal medicine, Cancer, Prostate and Cancer research. His Prostate cancer study combines topics in areas such as Genome-wide association study and Randomized controlled trial, Pathology. David E. Neal combines subjects such as Case-control study and Genetic association with his study of Genome-wide association study.
The Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology, Gynecology and Oncology. In his work, Genetic heterogeneity, DNA sequencing, Genomics, Point mutation and Genome is strongly intertwined with Bioinformatics, which is a subfield of Cancer. His Prostate study combines topics from a wide range of disciplines, such as Androgen and Adenocarcinoma.
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer and Prostate. His Prostate cancer research incorporates themes from Cancer research, Gynecology and Genome-wide association study, Single-nucleotide polymorphism. Internal medicine is closely attributed to Endocrinology in his study.
His Oncology research is multidisciplinary, incorporating perspectives in Stage and Disease. David E. Neal works on Cancer which deals in particular with Breast cancer. The various areas that David E. Neal examines in his Bladder cancer study include Urinary bladder and Pathology.
His scientific interests lie mostly in Prostate cancer, Internal medicine, Oncology, Cancer and Prostate. David E. Neal has included themes like Cancer research, Genome-wide association study, Single-nucleotide polymorphism, Randomized controlled trial and Hazard ratio in his Prostate cancer study. His studies deal with areas such as Breast cancer, Computational biology and Genetic association as well as Genome-wide association study.
His research integrates issues of Endocrinology and Gynecology in his study of Internal medicine. His research on Oncology also deals with topics like
His primary areas of investigation include Prostate cancer, Internal medicine, Oncology, Cancer and Genome-wide association study. His Prostate cancer research is multidisciplinary, incorporating elements of Cancer research, Prostate, Randomized controlled trial and Single-nucleotide polymorphism. His research in Internal medicine intersects with topics in Endocrinology and Gynecology.
David E. Neal interconnects Colorectal cancer, Case-control study and Confidence interval in the investigation of issues within Oncology. His research investigates the connection between Cancer and topics such as Mendelian randomization that intersect with issues in Menarche, Tanner scale, Gerontology, Vitamin D and neurology and Vitamin. His Genome-wide association study research includes elements of Expression quantitative trait loci, Lung cancer and Genetic association.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Freddie C. Hamdy;Jenny L. Donovan;J. Athene Lane;Malcolm Mason.
(2016)
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
(2020)
The evolutionary history of lethal metastatic prostate cancer.
Gunes Gundem;Peter Van Loo;Peter Van Loo;Peter Van Loo;Barbara Kremeyer;Ludmil B. Alexandrov.
Nature (2015)
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan Jl;Hamdy Fc;Lane Ja;Mason M.
(2016)
CD133, a novel marker for human prostatic epithelial stem cells
Gavin D. Richardson;Craig N. Robson;Shona H. Lang;David E. Neal.
Journal of Cell Science (2004)
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A Eeles;Rosalind A Eeles;Zsofia Kote-Jarai;Graham G Giles;Graham G Giles;Ali Amin Al Olama.
Nature Genetics (2008)
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.
DavidE. Neal;DavidE. Neal;MarkK. Bennett;MarkK. Bennett;ReginaldR. Hall;ReginaldR. Hall;Colin Marsh;Colin Marsh.
The Lancet (1985)
Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult.
Jenny Donovan;Nicola Mills;Monica Smith;Lucy Brindle.
BMJ (2002)
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Kalipso Halkidou;Luke Gaughan;Susan Cook;Hing Y. Leung.
The Prostate (2004)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Rosalind A. Eeles;Ali Amin Al Olama;Sara Benlloch;Edward J. Saunders.
Nature Genetics (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Oxford
University of Bristol
University of Bristol
Institute of Cancer Research
University of Melbourne
University of Manchester
Institute of Cancer Research
University of Utah
Fred Hutchinson Cancer Research Center
University of Copenhagen
Stanford University
Google (United States)
Nankai University
Centre national de la recherche scientifique, CNRS
University of New South Wales
Saint Louis University
KIIT University
Kobe Gakuin University
Kyoto University
Grenoble Alpes University
McGill University
University of Münster
University of Sussex
Uppsala University
University of Otago
University of Groningen